Efficacy and Safety of CBL-514 Injection in Reducing Abdominal Subcutaneous Fat: A Randomized, Single-Blind, Placebo-Controlled Phase II Study.

Background: A small-molecule injectable drug, CBL-514, has shown promising efficacy and safety for subcutaneous fat reduction.

Objectives: To further evaluate the efficacy and safety of CBL-514 for abdominal subcutaneous fat reduction.

Methods: In this single-blind, randomized, parallel-group, placebo-controlled Phase 2 trial, 76 participants were randomized (2:1) to receive up to four CBL-514 treatments (2mg/cm², maximum 600mg/treatment) or placebo, administered subcutaneously to the abdomen every 4 weeks.